中 En
x
Search

  • Made in China. Innovated in China.

  • Innovation. Purpose‑Driven. Gratitude. Learning. Teamwork. Passion.

  • Leading in Concept. Leading in Technology. Leading in Strategy.

  • Embrace every advance. Attract exceptional talent. Benefit all people. Achieve our very best.

About Hyperway

Guided by its corporate mission of “Develop Quality Medicines, Innovate in China,” Hyperway Pharma has built an international, highly specialized core R&D team equipped with forward‑looking strategic vision and robust innovation resources. Anchored in unmet clinical needs and driven by scientific advancement, the company is dedicated to developing First‑in‑Class (FIC) and Best‑in‑Class (BIC) targeted therapies. Hyperway Pharma is committed to becoming a globally influential biopharmaceutical innovator, continuously contributing to the improvement of human health.

Learn More
Founded in
2019
R&D Pipeline
15 +
Patent Application
70 +
Clinical Trials
5
  • Professional R&D Expertise
    Professional R&D Expertise
    Differentiated and accurate pipeline planning; Scientific and professional innovative drug design; Advanced and efficient synthesis of complex compounds; Competitive CMC research capabilities; Rapid execution in clinical development.
    Learn More
  • Differentiated R & D pipeline
    Differentiated R & D pipeline
    Focus on pain, cancer and other disease fields, select the validated cutting-edge advantage targets, strive to develop BIC / FIC innovative drugs, and take the lead in the layout of the future market.
    Learn More
  • Specialized Brain-Penetrant Drug Development Platform
    Specialized Brain-Penetrant Drug Development Platform
    Leveraging the Brain Penetration Platform as a vehicle, we are pooling our best resources to develop innovative drugs with strong brain penetration capabilities. This breakthrough aims to overcome the limitations of the blood-brain barrier and resolve the medication challenges faced by patients with brain disorders.
    Learn More

Pipeline Flagship Under Development

  • Novel Mechanism Analgesic Nav1.8 Inhibitor HBW-004285
    01Novel Mechanism Analgesic Nav1.8 Inhibitor HBW-004285

    Novel Mechanism Analgesic Nav1.8 Inhibitor HBW-004285

    The Nav1.8 inhibitor HBW-004285 has a brand-new analgesic mechanism and will not cause opioid addiction. It has outstanding advantages over the world's first drug with the same target in terms of safety, efficacy, and pharmacokinetic properties, and has the potential to become a BIC.
  • Reversible and noncovalent BTK inhibitor HBW-3220
    02Reversible and noncovalent BTK inhibitor HBW-3220

    Reversible and noncovalent BTK inhibitor HBW-3220

    HBW-3220 is a fourth generation BTK inhibitor with the fastest progress in the world, which can overcome the multiple drug-resistant mutations (such as C481S, L528W, T474I) produced by the first three generations of BTK inhibitors. The objective response rate (ORR) for CLL/SLL patients carrying C481S mutation can reach 100%, which is expected to fill the $10 billion market of BTKi for subsequent treatment.
  • KRAS G12D inhibitor HBW-012336
    03KRAS G12D inhibitor HBW-012336

    KRAS G12D inhibitor HBW-012336

    Preclinical studies demonstrate that HBW-012336 exhibits outstanding advantages including high potency, selectivity, tissue targeting and antitumor activity. It resolves the international challenge of poor oral bioavailability, presenting significant development value.
  • Pan-KRAS inhibitor HBW-012462
    04Pan-KRAS inhibitor HBW-012462

    Pan-KRAS inhibitor HBW-012462

    HBW-012462 demonstrates potent inhibition of multiple core KRAS mutations, exhibiting high potency, selectivity and tissue targeting advantages. It simultaneously suppresses both KRAS (ON) and KRAS (OFF) states, offering broader clinical applicability and promising therapeutic potential.
  • Potent brain penetrant and non-covalent BTK inhibitor HBW-3210
    05Potent brain penetrant and non-covalent BTK inhibitor HBW-3210

    Potent brain penetrant and non-covalent BTK inhibitor HBW-3210

    HBW-3210 is a fourth-generation non-covalent BTK inhibitor capable of overcoming resistance issues caused by the C481S mutation in first and second generation BTK inhibitors. Additionally, HBW-3210 exhibits strong brain penetration (brain penetration rate >60%), enabling it to effectively reach brain lesions and exert therapeutic effects.

Hyperway News